Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 6, 2003, Pages 499-502

  Mathew, Prasad ^a   Winter, Stuart S ^b   Frost, Jami D ^b   Hanrahan, Jeffrey ^b   Schwartz, Marcia ^b   Jones, Jane E ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Bleeding; Children; Disseminated intravascular coagulopathy; rFVIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD CLOTTING DISORDER; CARDIOPULMONARY BYPASS; CHILD; CLINICAL FEATURE; FEMALE; GLANZMANN DISEASE; HEMOPHILIA A; HEMOSTASIS; HEPATOBLASTOMA; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; BLOOD COAGULATION DISORDERS; CHILD, PRESCHOOL; FACTOR VII; FEMALE; HUMANS; INFANT, NEWBORN; MALE; RECOMBINANT PROTEINS;

EID: 0038277120     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200306000-00015     Document Type: Article

References (19)

1. Maureane H, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965
2. Shapiro A. Inhibitor treatment: State of the art. Semin Hematol 2001;38:26-34.
3. Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coag Fibrinolysis. 1998;9 (suppl):S147-S152.
4. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in hemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-778.
5. Nurden AT. George JN. Inherited abnormalities of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other disorders. In: Coleman RW, Hirsh J, Marder VJ, et al., eds. Hemostasis and Thrombosis. Basic Principles & Clinical Practice, edn. 4. Philadelphia: Lippincott Williams & Wilkins, 2001;921-943.
6. d'Orion R, Menart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann thrombasthenia undergoing invasive procedures. Thromb Haemost 2000;83:644-647.
7. Poon M-C, d'Orion R, Hann I, et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann Thrombasthenia. Semin Hematol 2001;38:21-25.
8. Rapaport SI: Coagulation problems in liver disease. Blood Coag Fibrinolysis 2000;11 (suppl):S69-S74.
9. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997;113:1930-1937.
10. Mariani G, Testa MG, Di Paolantonio T, et al. Use of recombinant, activated factor VII in the treatment of congenital factor deficiencies. Vox Sang 1999;77: 131-136.
11. Hunault M, Bauer KA. Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Sem Thromb Hemost 2000;21:401-405.
12. Taylor FB, Toh C-H, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330.
13. Wada H, Sakuragawa N, Mori Y, et al. Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 1999;60:273-278.
14. Despond O, Proulx F, Carcillo JA, et al. Pediatric sepsis and multiple organ dysfunction syndrome. Curr Opin Pediatr 2001;13:247-253.
15. Shorr AF, Trotta RF, Alkins SA, et al. D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease. Intensive Care Med 1999;25:207-210.
16. Ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000;28:S9-S11.
17. Mesters RM, Mannucci PM, Coppola R, et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88:881-886.
18. Taylor FB. Response of anticoagulant pathways in disseminated intravascular coagulation. Semin Hem Thromb 2001;27:619-638.
19. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-439.